BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of Momenta Pharmaceuticals, Inc. (“Momenta” or the “Company”) (NASDAQ: MNTA) investors concerning the Company and its officers’ possible violations of federal securities laws.
On February 17, 2017, Momenta revealed that a contracted Pfizer facility was in receipt of a warning letter from the U.S. Food and Drug Administration ("FDA"). Three days later, analysts from Leerink Capital Partners LLC stated that the FDA letter is alarming due to the fact that manufacturing warning letters can take years to resolve, and that a lengthy delay could hurt Momenta's market opportunity for its Glatopa 40mg product candidate.
On this news, Momenta's share price has fallen as much as $4.30, or 22.63%, during intraday trading on February 21, 2017.
If you purchased Momenta securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to email@example.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.